LivaNova Reports First Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Livanova (LIVN) PT Lowered to $87 at Needham & Company
May 1, 2019 12:10 PM EDTNeedham & Company analyst Mike Matson lowered the price target on Livanova (NASDAQ: LIVN) to $87.00 (from $100.00) while maintaining a Buy rating.
The analyst commented, "LIVN's 1Q19 revenue was consistent with its preannouncement and its EPS was below consensus. As expected, management lowered its 2019 revenue... More
LivaNova plc (LIVN) Misses Q1 EPS by 3c, Revenues Miss; FY19 EPS Guidance Below Consensus
May 1, 2019 6:17 AM EDTLivaNova plc (NASDAQ: LIVN) reported Q1 EPS of $0.54, $0.03 worse than the analyst estimate of $0.57. Revenue for the quarter came in at $250.8 million versus the consensus estimate of $255.87 million.
"We are disappointed by our first quarter performance in U.S. Neuromodulation and Perceval® sales. As a leadership team, we are implementing a series of actions to counteract the market dynamic and salesforce retention issues we experienced," said Damien McDonald, Chief Executive Officer of LivaNova. "Sales results for first quarter 2019 were strong in Cardiovascular across all... More
